Antônio Sérgio Cordeiro da Rocha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antônio Sérgio Cordeiro da Rocha has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Ademir Batista da Cunha
Antonio Pedro University Hospital Fluminense Federal University Niterói RJ Brazil
1 shared publication Alexandre Siciliano Colafranceschi
1 shared publication- André Volschan
Hospital Pró-Cardíaco, Brasil
1 shared publication Carlos Augusto Lobbe Cotta Ferreira
1 shared publicationCésar Nascimento
Instituto Nacional de Cardiologia Laranjeiras, Niterói
1 shared publicationDany Kruczan
1 shared publication
Latest Publications
- Open Access
- 14 August 2026
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
- Vol. 39
Asymptomatic Patients With Suspected Coronary Artery Disease: What Are Clinicians Afraid Of?
Introduction In contemporary practice, myocardial revascularization, particularly Percutaneous Coronary Intervention (PCI), is frequently performed in asymptomatic individuals with suspected Coronary Artery Disease (CAD). This occurs despite robust evidence from Randomized Clinical Trials (RCTs) over the past two decades demonstrating that, in patients with Chronic Coronary Syndromes (CCS), neither PCI nor Coronary Artery Bypass Grafting (CABG) reduces mortality when compared with Guideline-directed Medical Therapy (GDMT). In selected populations, revascularization confers symptomatic relief, particularly among patients with frequent angina, but without prognostic [...] Introduction In contemporary practice, myocardial revascularization, particularly Percutaneous Coronary Intervention (PCI), is frequently performed in asymptomatic individuals with suspected Coronary Artery Disease (CAD). This occurs despite robust evidence from Randomized Clinical Trials (RCTs) over the past two decades demonstrating that, in patients with Chronic Coronary Syndromes (CCS), neither PCI nor Coronary Artery Bypass Grafting (CABG) reduces mortality when compared with Guideline-directed Medical Therapy (GDMT). In selected populations, revascularization confers symptomatic relief, particularly among patients with frequent angina, but without prognostic
- 14 August 2026
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
- Vol. 39
Open AccessAsymptomatic Patients With Suspected Coronary Artery Disease: What Are Clinicians Afraid Of?
Introduction In contemporary practice, myocardial revascularization, particularly Percutaneous Coronary Intervention (PCI), is frequently performed in asymptomatic individuals with suspected Coronary Artery Disease (CAD). This occurs despite robust evidence from Randomized Clinical Trials (RCTs) over the past two decades demonstrating that, in patients with Chronic Coronary Syndromes (CCS), neither PCI nor Coronary Artery Bypass Grafting (CABG) reduces mortality when compared with Guideline-directed Medical Therapy (GDMT). In selected populations, revascularization confers symptomatic relief, particularly among patients with frequent angina, but without prognostic [...] Introduction In contemporary practice, myocardial revascularization, particularly Percutaneous Coronary Intervention (PCI), is frequently performed in asymptomatic individuals with suspected Coronary Artery Disease (CAD). This occurs despite robust evidence from Randomized Clinical Trials (RCTs) over the past two decades demonstrating that, in patients with Chronic Coronary Syndromes (CCS), neither PCI nor Coronary Artery Bypass Grafting (CABG) reduces mortality when compared with Guideline-directed Medical Therapy (GDMT). In selected populations, revascularization confers symptomatic relief, particularly among patients with frequent angina, but without prognostic
- Open Access
- 14 November 2024
- Published by Instituto Nacional de Cardiologia - Brazil in OnScience
- Vol. 2 (2) , e0022-e00022
Criticism to the revascularization indications attained in the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease
Clinical practice guidelines are valuable tools that guide doctors' conduct in a series of diseases with high prevalence in the population. The 2023 guideline on chronic coronary disease (CCD), written by the American Heart Association and the American College of Cardiology in conjunction with other American entities is no exception to this rule and although it is designed for application in American medical practice, it gains relevance for use in care of patients affected by this disease worldwide 1. The guidelines help healthcare professionals the best decision-making, with the aim of offering the best possible care to patients, aligned with their expectations, needs and interests. Furthermore, they are important documents for governments, payers and healthcare providers by providing a set of recommendations that help and guide decisions about coverage of diagnostic and therapeutic procedures related to diseases with high prevalence in the population. In this 2023 guideline, the authors say that revascularization is an evolving topic and emphasize that recommendations are typically based on the results of larger randomized controlled trials (RCTs), meta-analyses, or both encompassing a wide range of knowledge on the subject. but they recognize that RCTs do not cover all the nuances involved with the topic, nor do they address all issues comprehensively. Based on this, they made a concentrated effort to stay within the strongest evidence to define these revascularization recommendations in patients with CCD. Within this principle, reviewing chapter 5 dedicated specifically to myocardial revascularization, we are concerned, among other things, with the recommendations resulting from the analysis of some studies that do not clearly reflect the reality of contemporary care provided to patients with CCD, in addition to events that do not reflect the primary outcomes of many of these studies. For this reason, we performed a careful review of the most relevant randomized controlled trials (RCTs), systematic reviews and meta-analyses used in the guideline for revascularization recommendations, which impact a significant number of patients affected by CCD worldwide.
- 14 November 2024
- Published by Instituto Nacional de Cardiologia - Brazil in OnScience
- Vol. 2 (2) , e0022-e00022
Open AccessCriticism to the revascularization indications attained in the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease
Clinical practice guidelines are valuable tools that guide doctors' conduct in a series of diseases with high prevalence in the population. The 2023 guideline on chronic coronary disease (CCD), written by the American Heart Association and the American College of Cardiology in conjunction with other American entities is no exception to this rule and although it is designed for application in American medical practice, it gains relevance for use in care of patients affected by this disease worldwide 1. The guidelines help healthcare professionals the best decision-making, with the aim of offering the best possible care to patients, aligned with their expectations, needs and interests. Furthermore, they are important documents for governments, payers and healthcare providers by providing a set of recommendations that help and guide decisions about coverage of diagnostic and therapeutic procedures related to diseases with high prevalence in the population. In this 2023 guideline, the authors say that revascularization is an evolving topic and emphasize that recommendations are typically based on the results of larger randomized controlled trials (RCTs), meta-analyses, or both encompassing a wide range of knowledge on the subject. but they recognize that RCTs do not cover all the nuances involved with the topic, nor do they address all issues comprehensively. Based on this, they made a concentrated effort to stay within the strongest evidence to define these revascularization recommendations in patients with CCD. Within this principle, reviewing chapter 5 dedicated specifically to myocardial revascularization, we are concerned, among other things, with the recommendations resulting from the analysis of some studies that do not clearly reflect the reality of contemporary care provided to patients with CCD, in addition to events that do not reflect the primary outcomes of many of these studies. For this reason, we performed a careful review of the most relevant randomized controlled trials (RCTs), systematic reviews and meta-analyses used in the guideline for revascularization recommendations, which impact a significant number of patients affected by CCD worldwide.
- 20 May 2022
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
Chronic Coronary Syndrome: Medical Therapy or Myocardial Revascularization?
The best therapeutic strategy for chronic coronary syndrome (CCS) is still controversial. The lack of contemporaneity of medical treatment in many randomized clinical trials prior to the large-scale use of statins, antiplatelet agents, anti-diabetic drugs with cardiovascular protection, and changes in life habits with well-established goals limits the applicability of such studies in current clinical practice. Medical treatment is the only therapeutic option capable of reducing atherosclerotic damage and, therefore, of acting effectively in preventing the progression of this [...] Abstract The best therapeutic strategy for chronic coronary syndrome (CCS) is still controversial. The lack of contemporaneity of medical treatment in many randomized clinical trials prior to the large-scale use of statins, antiplatelet agents, anti-diabetic drugs with cardiovascular protection, and changes in life habits with well-established goals limits the applicability of such studies in current clinical practice. Medical treatment is the only therapeutic option capable of reducing atherosclerotic damage and, therefore, of acting effectively in preventing the progression of this
- 20 May 2022
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
Chronic Coronary Syndrome: Medical Therapy or Myocardial Revascularization?
The best therapeutic strategy for chronic coronary syndrome (CCS) is still controversial. The lack of contemporaneity of medical treatment in many randomized clinical trials prior to the large-scale use of statins, antiplatelet agents, anti-diabetic drugs with cardiovascular protection, and changes in life habits with well-established goals limits the applicability of such studies in current clinical practice. Medical treatment is the only therapeutic option capable of reducing atherosclerotic damage and, therefore, of acting effectively in preventing the progression of this [...] Abstract The best therapeutic strategy for chronic coronary syndrome (CCS) is still controversial. The lack of contemporaneity of medical treatment in many randomized clinical trials prior to the large-scale use of statins, antiplatelet agents, anti-diabetic drugs with cardiovascular protection, and changes in life habits with well-established goals limits the applicability of such studies in current clinical practice. Medical treatment is the only therapeutic option capable of reducing atherosclerotic damage and, therefore, of acting effectively in preventing the progression of this
- 25 August 2021
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
Predictive Value of Myocardial injury in Patients with COVID-19 Admitted to a Quaternary Hospital in the City of Rio de Janeiro
Background In Brazil the factors involved in the risk of death in patients with COVID-19 have not been well established. Objective To analyze whether elevations of high-sensitivity troponin I (hTnI) levels influence the mortality of patients with COVID-19. Methods Clinical and laboratory characteristics of hospitalized patients with COVID-19 were collected upon hospital admission. Univariate and binary logistic regression analyzes were performed to assess the factors that influence mortality. P-value50% in chest computed tomography (P=0.011), with previous coronary artery disease [...] Abstract Background In Brazil the factors involved in the risk of death in patients with COVID-19 have not been well established. Objective To analyze whether elevations of high-sensitivity troponin I (hTnI) levels influence the mortality of patients with COVID-19. Methods Clinical and laboratory characteristics of hospitalized patients with COVID-19 were collected upon hospital admission. Univariate and binary logistic regression analyzes were performed to assess the factors that influence mortality. P-value50% in chest computed tomography (P=0.011), with previous coronary artery disease
- 25 August 2021
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
Predictive Value of Myocardial injury in Patients with COVID-19 Admitted to a Quaternary Hospital in the City of Rio de Janeiro
Background In Brazil the factors involved in the risk of death in patients with COVID-19 have not been well established. Objective To analyze whether elevations of high-sensitivity troponin I (hTnI) levels influence the mortality of patients with COVID-19. Methods Clinical and laboratory characteristics of hospitalized patients with COVID-19 were collected upon hospital admission. Univariate and binary logistic regression analyzes were performed to assess the factors that influence mortality. P-value50% in chest computed tomography (P=0.011), with previous coronary artery disease [...] Abstract Background In Brazil the factors involved in the risk of death in patients with COVID-19 have not been well established. Objective To analyze whether elevations of high-sensitivity troponin I (hTnI) levels influence the mortality of patients with COVID-19. Methods Clinical and laboratory characteristics of hospitalized patients with COVID-19 were collected upon hospital admission. Univariate and binary logistic regression analyzes were performed to assess the factors that influence mortality. P-value50% in chest computed tomography (P=0.011), with previous coronary artery disease
- Open Access
- 1 January 2007
- Published by FapUNIFESP (SciELO) in Arquivos Brasileiros de Cardiologia
- Vol. 88 (1) , e1-e3
Mixoma em átrio esquerdo associado a doença arterial coronariana obstrutiva
We describe a case of a 67 year-old patient with obstructive coronary artery disease that, in the preoperative survey for inguinal herniorraphy surgery, discovered, by a two-dimensional echocardiogram, a tumor in left atrium, mobile, non-obstructive. The patient underwent a cineangiocoronariography showing severe stenosis in the left anterior descending artery, moderate stenosis in the left circumflex artery, near the origin of the first marginal branch, and a non-obstructive plaque in the right coronary artery. There was also moderate left ventricular dysfunction. After that, the patient has gone coronary artery bypass surgery and resection of the left atrial tumor. The histological exam revealed that the tumor was, in fact, a myxoma.
- 1 January 2007
- Published by FapUNIFESP (SciELO) in Arquivos Brasileiros de Cardiologia
- Vol. 88 (1) , e1-e3
Open AccessMixoma em átrio esquerdo associado a doença arterial coronariana obstrutiva
We describe a case of a 67 year-old patient with obstructive coronary artery disease that, in the preoperative survey for inguinal herniorraphy surgery, discovered, by a two-dimensional echocardiogram, a tumor in left atrium, mobile, non-obstructive. The patient underwent a cineangiocoronariography showing severe stenosis in the left anterior descending artery, moderate stenosis in the left circumflex artery, near the origin of the first marginal branch, and a non-obstructive plaque in the right coronary artery. There was also moderate left ventricular dysfunction. After that, the patient has gone coronary artery bypass surgery and resection of the left atrial tumor. The histological exam revealed that the tumor was, in fact, a myxoma.
- Open Access
- 1 April 1999
- Published by FapUNIFESP (SciELO) in Arquivos Brasileiros de Cardiologia
- Vol. 72 (4) , 479-482
Aortic stenosis. Gender influence on left ventricular geometry and function in patients under 70 years of age
To verify if adaptive left ventricle (LV) characteristics are also present in individuals under 70 years of age with severe aortic stenosis (AS). The study comprised 40 consecutive patients under 70 years of age with AS and no associated coronary artery disease, referred for valve surgery. Out of the 40 patients, 22 were men and 18 women, and the mean age was 49.8 +/- 14.3 years. Cardiac symptoms, presence of systemic hypertension (SH), functional class according to the New York Heart Association (NYHA), and valve lesion etiology were considered. LV cavity dimensions, ejection fraction (EF), fractional shortening (FS), mass (MS), and relative diastolic thickness (RDT) were examined by Doppler echocardiography. Fourteen (63.6%) men and 11 (61.6%) women were classified as NYHA class III/IV (p = 0.70). There was no difference in the frequency of angina, syncope or dyspnea between genders. The incidence of SH was greater in women than in men (10 versus 2, p = 0.0044). Women had a smaller LV end-diastolic diameter index (32.1 +/- 6.5 x 36.5 +/- 5.3 mm/m2, p = 0.027), LV end-systolic diameter index (19.9 +/- 5.9 x 26.5 +/- 6.4 mm/m2, p = 0.0022) and LV mass index (MS) (211.4 +/- 71.1 x 270.9 +/- 74.9 g/m2, p = 0.017) when compared with men. EF (66.2 +/- 13.4 x 52.0 +/- 14.6%, p = 0.0032), FS (37.6 +/- 10.7 x 27.9 +/- 9.6%, p = 0.0046) and RDT (0.58 +/- 0.22 x 0.44 +/- 0.09, p = 0.0095) were significantly greater in women than in men. It is the patient gender rather than age that influences left ventricular adaptive response to AS.
- 1 April 1999
- Published by FapUNIFESP (SciELO) in Arquivos Brasileiros de Cardiologia
- Vol. 72 (4) , 479-482
Open AccessAortic stenosis. Gender influence on left ventricular geometry and function in patients under 70 years of age
To verify if adaptive left ventricle (LV) characteristics are also present in individuals under 70 years of age with severe aortic stenosis (AS). The study comprised 40 consecutive patients under 70 years of age with AS and no associated coronary artery disease, referred for valve surgery. Out of the 40 patients, 22 were men and 18 women, and the mean age was 49.8 +/- 14.3 years. Cardiac symptoms, presence of systemic hypertension (SH), functional class according to the New York Heart Association (NYHA), and valve lesion etiology were considered. LV cavity dimensions, ejection fraction (EF), fractional shortening (FS), mass (MS), and relative diastolic thickness (RDT) were examined by Doppler echocardiography. Fourteen (63.6%) men and 11 (61.6%) women were classified as NYHA class III/IV (p = 0.70). There was no difference in the frequency of angina, syncope or dyspnea between genders. The incidence of SH was greater in women than in men (10 versus 2, p = 0.0044). Women had a smaller LV end-diastolic diameter index (32.1 +/- 6.5 x 36.5 +/- 5.3 mm/m2, p = 0.027), LV end-systolic diameter index (19.9 +/- 5.9 x 26.5 +/- 6.4 mm/m2, p = 0.0022) and LV mass index (MS) (211.4 +/- 71.1 x 270.9 +/- 74.9 g/m2, p = 0.017) when compared with men. EF (66.2 +/- 13.4 x 52.0 +/- 14.6%, p = 0.0032), FS (37.6 +/- 10.7 x 27.9 +/- 9.6%, p = 0.0046) and RDT (0.58 +/- 0.22 x 0.44 +/- 0.09, p = 0.0095) were significantly greater in women than in men. It is the patient gender rather than age that influences left ventricular adaptive response to AS.